After hours JUNO price is about $65. There are 114M shares outstanding giving it a market cap of about $7.4B.
In my opinion, JUNO should be worth more than KITE. It has better efficacy and better safety. Drug is not yet approved but I think there’s a VERY high chance of approval, probably later this year or in early 2019.
This is all speculation but I think a $65 acquisition price is too low. At that price, you might see another suitor. CELG won’t let JUNO go to another company. A $100 acquisition price would mean a market cap of $11.4B which is in the ballpark of what GILD paid for KITE. My guess is that JUNO will ultimately sell for $100. But again this is merely speculation and I’m not betting on it. I’m just holding my existing shares for now.